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Summary 
Phagocyte recognition and ingestion of intact cells undergoing apoptosis are key events in this 
generally important program of cell death. Insufficient phagocyte capacity for apoptotic cells 
can result in failure to clear dying cells before membrane integrity is lost, resulting in leakage 
of noxious cell contents and severe tissue damage. However, no means has been available to increase 
phagocytic clearance of apoptotic cells. We now report that transfection of the macrophage adhesion 
molecule CD36 into human Bowes melanoma cells specifically conferred greatly increased capacity 
to ingest apoptotic neutrophils, lymphocytes, and fibroblasts,  comparable to that exhibited by 
macrophages. Furthermore, when CD36 was transfected into another cell type with limited capacity 
to take up apoptotic bodies, the monkey COS-7 cell,  similar effects were observed. Therefore, 
CD36 gene transfer can confer "professional" capacity to ingest apoptotic cells upon "amateur" 
phagocytes. 
C 
ell clearance by apoptosis protects surrounding tissues 
from damage due to uncontrolled leakage of noxious 
contents from dying cells  (1-6).  Intact apoptotic cells can 
be taken up in vivo by neighboring cells, often of the same 
type, acting as "amateur" phagocytes. Where the load of apop- 
totic cells is high, as in the thymus (7) or inflamed site (3, 
8), this job is done by "professional" phagocytes, macrophages, 
which can dear large numbers of apoptotic cells. Neverthe- 
less, this normally efficient clearance system can fail (8, 9). 
A dramatic example was recently afforded by intraperitoneal 
administration of antibody to Fas, which triggered rapid and 
widespread hepatocyte apoptosis (9).  However, presumably 
because of insufficient local capacity to clear an unphysiolog- 
ically massive load of apoptotic cells, hepatocytes disintegrated 
and coagulative necrosis of the liver and death rapidly ensued 
(9).  This  is  an important  observation,  because there is  a 
growing interest in the possibility that selective triggering 
of apoptosis might be useful in deleting dangerous cells from 
the body, such as tumor cells or auto-reactive lymphocytes 
(10). Unless local phagocytic capacity is able to cope with 
a massive increase in load of apoptotic cells,  such putative 
treatments could have dire effects on surrounding tissues. Con- 
sequently, we sought a means to confer increased capacity 
for uptake of apoptotic cells. 
Mechanisms by which phagocytes recognize cells under- 
going apoptosis are incompletely understood (6).  However, 
mAb inhibition experiments suggested that human monocyte- 
derived macrophages (Me) can employ the adhesion receptor 
CD36 (11, 12) in high capacity phagocytosis of apoptotic neu- 
trophils and lymphocytes (4, 5). The data suggest that Me 
CD36 cooperates with Me c~v33 vitronectin receptor inte- 
grin to bind the adhesive glycoprotein thrombospondin (TSP), 
which then acts as a "molecular bridge" binding the Me to 
the apoptotic cell (4, 5). However, a role for CD36 in phago- 
cytosis had not been demonstrated directly. In this study we 
investigated whether CD36 gene transfer can confer phago- 
cytic capacity for cells undergoing apoptosis. 
Materials  and Methods 
Phagocytes Used in the Study.  Bowes  melanoma cells (gift of Dr. 
D. B. Rifkin, New York University Medical Center) were stably 
transfected as previously described (12) with pMV7 neomycin re- 
sistance vector (control) or vector incorporating CD36cDNA and 
selected in medium with G418 (250 ~g/ml). By flow cytometry 
(13, and not shown) >80% ofCD36+ Bowes  cells expressed  CD36 
at levels comparable to Mo. 
COS-7 cells (from American Type Culture Collection, Rock- 
ville, MD) were transiently transfected with cdm8 vector bearing 
either CD36  eDNA or FcR1(p135) eDNA by standard DEAE 
dextran-mediated transfection, as described (12, 14). Comparable 
levels of CD36 and Fell 1 expression were obtained. With regard 
to CD36, these were "~10-fold  lower than the high levels of CD36 
expression achieved  by stable transfection  of Bowes cells (not shown). 
In common with Bowes cells, COS-7 cells  expressed  epitopes  bound 
by 23C6 cr  mAb. 
Apoptotic Cells Used in the Study.  In all cases, apoptotic cells 
were obtained by well-established protocols, had viability >95% 
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tures of apoptosis. 
Neutrophils used were prepared from normal human peripheral 
blood and "aged" in culture in 24 h  so as to undergo  apoptosis, 
exactly as described  (3). 
Lymphocytes used were a B-cell line derived from MUTU-BL 
Burkitt Lymphoma Group i  cells (gift ofJ. Hickman, University 
of Manchester, UK; refrence 15), which were triggered to undergo 
apoptosis by culture in serum-free RPMI medium for 48 h; nonapop- 
totic cells were harvested from cultures in RPMI plus 10% FCS. 
Fibroblasts used were SV40-transformed murine 3T3 fibroblasts 
(gift of D. Ucker, Medical Biology Institute, La Jolla,  CA; refer- 
ence 16), and were triggered to undergo  apoptosis by culture in 
serum-free RPMI medium for 24 h. 
Phagocytosis Assays.  Bowes  cells  were  subcultured  in  DME 
medium plus 10%  FCS as adherent monolayers in 96-well tissue 
culture  plates,  washed,  and  then  interacted  by well-established 
methods (3-5,  17) for 3 h with 105 per well apoptotic cells in the 
same medium. Noningested apoptotic cells were then washed away 
with cold saline. In some experiments, monolayers were fixed with 
2% glutaraldehyde and then stained for myeloperoxidase to reveal 
ingested apoptotic neutrophils,  as described (16). However, for quan- 
titation of phagocytosis, the monolayer was trypsinized at the end 
of the interaction and a cytocentrifuge preparation made from each 
well, which  was fixed  and  stained with  Haemalum to reveal in- 
gested apoptotic cells; in neutrophil experiments the cytopreps were 
also counterstained with myeloperoxidase.  The proportion of Bowes 
cells ingesting apoptotic cells in each cytoprep was then determined 
by microscopical counting  of 300 Bowes cells per slide.  In some 
experiments, data were also presented as the number of ingested 
PMNs per 100 Bowes cells.  In further experiments, at the end of 
a phagocytosis assay, trypsinized Bowes CD36+  cells were pre- 
pared for EM by standard  methods. 
COS-7 cells were grown in 24-well plates in RPMI 1640 medium 
plus 10%  FCS,  and then interacted with apoptotic cells by iden- 
tical methods to those used for Bowes cells. COS-7 cells were as- 
sessed 48  h  after transfection. 
Inhibitors were included directly in the interaction medium (at 
the concentrations  given below or in  the figure legend). 
Antibodies Used in Phagocytosis  Assays.  The mAbs used have all 
been employed before in studies of phagocyte recognition of apop- 
totic cells (4,  5,  18), and no mAb inhibited human Mo phagocy- 
tosis of opsonized erythrocytes in control experiments. The CD36 
mAb (OKM5; IgG1; reference 19) and B3 mAb (15.4.2; IgG1; gift 
of M.  Ginsburg,  Scripps  Research Institute,  La Jolla,  CA;  refer- 
ence 20) were employed at 50/~g/ml. mAb to Thyl.1 (OX7; used 
as irrelevant control IgG1; from Serotec,  Banbury, UK), the c~v~3 
mAb (23C6;  IgG1; gift of M.  Horton,  St. Bartholomew's Hos- 
pital, London, UK; reference 21), the thrombospondin mAb (C6.7; 
IgG1; gift of V. Dixit; reference 22),  a second CD36 mAb (SMo; 
IgM; gift of Dr. N. Hogg, Imperial Cancer Research Fund; refer- 
ence 23),  and a CD15 mAb (mAb 28;  IgM control for SMo; gift 
of Dr. N. Hogg, reference 23) were used at 1:50 dilution of ascites. 
Other Inhibitors.  Phospho-t-serine (Sigma Immunochemicals, 
St.  Louis,  MO) was used at  1 mM (24,  25).  Soluble CD36 was 
prepared as described (13, 26),  and human fibronectin was from 
Calbiochem (Cambridge Bioscience,  UK). 
Results 
Transfection of Bowes Cells with CD36  Confers Capacity.for 
Phagocytosis ofApoptotic Neutrophils.  The human Bowes mela- 
Figure  1.  Enhanced  phagocytosis 
of apoptotic neutrophils by Bowes 
melanoma cells stably transfected 
with CD36 (examples  arrowed). (a) 
Appearance of washed monolayers 
of CD36+  (left) and vector-only 
control  (right) Bowes cells at end 
of 3 h interaction with apoptotic 
neutrophils;  x 200.  Note  much 
greater number of myeloperoxidase- 
positive, brown-staining apoptotic 
neutrophils bound by CD36+  cells; 
nuclei are not stained by this tech- 
nique (b) Cytocentrifuge  preparation 
ofCD36+ Bowes cells trypsinized 
after interaction, demonstrating  pha- 
gocytosis of apoptotic neutrophils; 
x 1000. Note condensed chromatin 
of ingested cells. (c) Electron micro- 
graph (x 2000) of CD36 +  Bowes 
cell demonstrating  uptake  of  neutro- 
phil with typical features of apop- 
tosis (N). 
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Figure 2.  Specificity of CD36 + Bowes melanoma cell phagocytosis of 
apoptotic neutrophils.  (a)  Negligible phagocytosis of freshly  isolated 
nonapoptotic neutrophils and opsonized erythrocytes by CD36 +  Bowes 
cells, and minimal phagocytosis of apoptotic neutrophils by Bowes cells 
transfected  with pMV7 vector alone.  *p <0.05.  (b) CD36+  Bowes cell 
noma cell line is known not to express CD36,  or to bind 
TSP (13),  but did expression otv33 when assessed by flow 
cytometry (data not shown). When stably transfected with 
pMV7 neomycin resistance vector bearing CD36, there was 
no detectable change in otv33 expression versus Bowes cells 
transfected with vector alone, while CD36 was expressed at 
a high level comparable to Me (13). When compared with 
Bowes cells transfected with vector alone, CD36+  Bowes 
cells exhibited a dramatically increased capacity to ingest apop- 
totic neutrophils (Figs. 1 and 2 a), which approximated that 
exhibited by human monocyte-derived macrophages (',,40% 
of which take up apoptotic neutrophils; reference 3).  This 
increase was also apparent when phagocytosis was expressed 
as the number of apoptotic neutrophils ingested per 100 Bowes 
cells (5  _+  2.0 for vector alone and 55  +  10.5 for CD36+ 
Bowes cells). CD36 transfection did not cause a nonspecific 
stimulation of phagocytic activity because CD36+  Bowes 
cells did not ingest freshly isolated, nonapoptotic neutrophils, 
nor did they take up IgG-opsonized erythrocytes, used as a 
control particle (Fig.  2 a). 
Conferred Phagocytosis  Mimics the Recognition  Mechanism Em- 
ployed by Human M~  There was clear evidence that trans- 
fected CD36 was functioning in conferred phagocytosis.  First, 
soluble CD36 exerted specific concentration-dependent in- 
hibition of phagocytosis of apoptotic neutrophils by CD36 + 
Bowes cells (Fig.  2 b and Table 1). Second, the IgG1 CD36 
mAb OKM5 (which does not bind apoptotic neutrophils), 
but not an isotype control mAb, inhibited ingestion of apop- 
totic neutrophils (Fig. 2 c and Table 2). In keeping with our 
previous observations on human Me, we found that uptake 
of apoptotic  neutrophils  was  inhibited by Otv/33 and TSP 
mAbs, suggesting that in Bowes cells CD36 also cooperated 
with these structures as proposed for the M0 (5). Moreover, 
phagocytosis was not affected by inhibitors of the other major 
macrophage mechanism for ingestion of apoptotic neutro- 
phils, recognition of exposed phosphatidylserine (PS) by puta- 
tive PS receptors (PSR;  Fig.  2 c and Table 2)  (24,  25). 
CD36 Confers Capacity to Recognize  Apoptotic Cells of Other 
Lineages.  We assessed whether transfected CD36 specifically 
conferred increased capacity to ingest apoptotic cells other 
than neutrophils. CD36 +  Bowes cells took up apoptotic lym- 
phocytes significantly more avidly than Bowes cells transfected 
with vector alone; nonapoptotic lymphocytes were not rec- 
ognized by transfectants. Furthermore, specificity of recog- 
nition of apoptotic lymphocytes was confirmed by the in- 
hibitory effects of soluble CD36 and mAbs to CD36,  TSP 
and ~/33; PSR inhibitor had no effect. (Fig.  3 a). Identical 
results were obtained with apoptotic fibroblasts (Fig.  3 b), 
demonstrating that CD36 can also confer capacity to phagocy- 
tize apoptotic cells of a nonleukocyte lineage. 
phagocytosis of apoptotic neutrophils is inhibited by soluble CD36, but 
not by fibronectin (Fn) control. [], Fn; O,  CD36.  (c) CD36+  Bowes 
cell phagocytosis of apoptotic neutrophils is inhibited by mAbs to CD36 
(OKM5),  otv~3 (23C6),  133 (15.4.2.),  and TSP (C6.7).  Irrelevant control 
mAb (OX7) and phospho-t-serine, an inhibitor of macrophage PS receptors, 
have no effect.  *p <0.05. 
1859  Ken et al.  Brief Definitive Report Table  1.  Soluble CD36 Specifically Inhibits the Phagocytic 
Capacity of CD36 +  Bowes  Cells for Apoptotic  Neutrophils 
Number of PMNs  ingested per 
100 Bowes cells 
Concentration  CD36  Fibronectin 
Nil (control)  47  •  8.0  - 
2  #g/ml  27  +  2.0  47  +  6.0 
5 #g/ml  25  +  3.0  41  +  5.5 
10 #g/ml  19  _+  0.5*  38  +  2.5 
20 #g/ml  12  _+  0.5*  37  _+  5.0 
Data are mean  _  SE, n  =  6.  *p <0.05  vs control. 
CD36  Transfection  Also  Confers Phagocytic  Capacity  upon 
COS-7  Cells.  To establish  that  the  ability  of transfection 
with CD36 to confer capacity for phagocytosis of apoptotic 
cells upon  Bowes cells was not  an idiosyncrasy of this  cell 
type, we transiently transfected COS-7 cells with cdm8 vector 
incorporating CD36 cDNA (12, 14). Despite yielding ,o10- 
fold lower levels of CD36 expression than stable transfection 
of Bowes cells,  this conferred specifically increased capacity 
to phagocytize apoptotic neutrophils  when compared with 
nontransfected  COS-7 cells,  or cells transfected with an ir- 
relevant  phagocytic receptor,  FcR1  (Fig.  4). 
Discussion 
CD36 (also known as glycoprotein IV) is an 88-kD mono- 
meric cell surface molecule expressed by a limited range of 
cell types, namely monocyte-macrophages, microvascular en- 
dothelium,  mammary epithelium,  platelets and megakaryo- 
cytes,  and  some erythroid  cells  (27).  CD36  was originally 
Table  2.  CD36 +  Bowes  Cell Phagocytosis of Apoptotic 
Neutrophils Exhibits  Characteristics of an ce~fl3 Vitronectin 
Receptor-dependent Rather  Than a Phosphatidylserine 
Receptor-dependent Mechanism 
Number of PMNs  ingested 
Inhibitor  per  100  Bowes cells 
Nil  (medium control)  56  _+  10.8 
OX7  (irrelevant mAb)  50  +  8.7 
OKM5  (CD36  mAb)  17  _+  1.5" 
C6.7  (TSP mAb)  15  •  5.6* 
23C6  (oM$3 mAb)  5  •  2.7* 
15.4.2  (/33 mAb)  17  +  2.0* 
Phospho-t-serine  60  _+  6.7 
Data are mean  +  SE, n  =  6.  *p <0.05 vs medium control.  Inhibitors 
were employed as described in Materials and Methods. 
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Figure  3.  CD36 + Bowes mehnoma cells specifically  phagocytize  apop- 
totic lymphocytes and fibroblasts. (a) Specific phagocytosis of apoptotic 
cells from B lymphocyte line. Note inhibition by soluble CD36 (at 10 
/zg/ml) and mAbs to CD36 (OKMS), otv/$3 (23C6), and TSP (C6. 7), to- 
gether with lack of effect of fibronectin (Fn, at 10 #g/ml) and irrelevant 
mAb (OXT) controls, and failure of phospho-t-serine (1 mM) to inhibit. 
Antibodies were used at concentrations given in Materials and Methods. 
Note also that nonapoptotic lymphocytes were not ingested by CD36+ 
Bowes cells, and that Bowes cells transfected with PMV7 vector alone 
exhibited minimal phagocytosis of apoptotic B cells. *p <0.05. (b) Specific 
phagocytosis of apoptotic transformed murine fibroblasts. The same in- 
hibitors were used. *p <0.05. 
characterized as an adhesion receptor for thrombospondin (11, 
26) and collagen (28), and was later implicated in microvas- 
cular endothelial cell binding of erythrocytes parasitized by 
Plasmodium falciparum  (29,  12).  Our  own  antibody inhibi- 
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Phagocytosis  of apoptotic  neutrophils by monkey  COS-7 cells 
transiently transfected with CD36. (a) Appearance of cytocentrifuge of 
trypsinized CD36-transfected  COS-7 cells  after 3-h interaction with apop- 
totic neutrophils. Note many COS-7 cells contain brown-staining apop- 
totic neutrophils (examples arrowed).  ￿  300. (b) Specificity  of phagocy- 
tosis. Note minimal ingestion of apoptotic neutrophils by COS-7 cells 
transfected with FoR1 (p135), an irrelevant phagocytic receptor. CD36 
mAb, but not irrelevant mAb 28, inhibits uptake of apoptotic  neutrophils 
by CD36-transfected cells. *p <0.05. 
tion  experiments  subsequently  implied  a  previously  un- 
suspected role for macrophage CD36 in mediating phagocy- 
tosis  of apoptotic  neutrophils  (5)  and  lymphocytes  (18). 
However, because cross-linking  of macrophage  CD36 was 
known to elicit signals such as superoxide generation  (30), 
it remained possible that such effects of CD36 mAbs might 
mediate spurious inhibition of Me phagocytosis of apoptotic 
neutrophils.  The  current  data  are therefore the  first direct 
demonstration that the functional repertoire of CD36 includes 
the capacity to promote efficient phagocytosis of apoptotic 
cells. 
This observation is also of potential  importance because 
it is the first example of a gene transfer  strategy by which 
clearance  of apoptotic  cells could be increased.  As under- 
standing  of the  mechanisms  by which  apoptotic  cells  are 
phagocytized grows, genes other than CD36 may be found 
to have similar capacity to promote clearance of cells being 
eliminated by this mechanism.  If treatments  are developed 
which induce apoptosis in undesirable cells (10), then it may 
be possible to bolster local phagocytic capacity against a mas- 
sively increased load of dying cells by targetting phagocytic 
genes to such sites. Because of its limited tissue distribution, 
CD36 holds some promise as a tool for promoting clearance 
of apoptotic cells in vivo. However, it will be important  to 
understand the molecular mechanisms of CD36-potentiated 
phagocytosis, which should include detailed investigation of 
functional  cooperation  with  the  0r  vitronectin  receptor 
integrin and thrombospondin as observed in human Me and 
CD36+  Bowes cells. 
Finally,  the current findings emphasize that the biological 
role of CD36 is not merely limited to that  of an adhesion 
molecule.  Recently,  CD36  has  been implicated  in endocy- 
tosis of oxidized low density lipoprotein  (31,  32) and fatty 
acids (33), and in phagocytosis of retinal photoreceptor outer 
segments (34). Whether CD36 has a wider role in phagocy- 
tosis and  endocytosis is worth  further  investigation. 
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